Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 3Cytokine Release Syndrome 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Neurilemmoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Burkitt Lymphoma 1Advanced Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 62Rituximab 47fludarabine 35fludarabine phosphate 27obinutuzumab 17Mycophenolic Acid 16ibrutinib 15Whole-Body Irradiation 15Lenalidomide 15Specimen Handling 14Prednisone 14venetoclax 13pirtobrutinib 13Etoposide 13Doxorubicin 13pembrolizumab 12Tacrolimus 12Magnetic Resonance Spectroscopy 11Granulocyte Colony-Stimulating Factor 11Filgrastim 11Biopsy 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10X-Rays 9Bendamustine Hydrochloride 9polatuzumab vedotin 8glofitamab 8acalabrutinib 8Immunotherapy, Adoptive 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × siltuximab × 1 year × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡